Beaner,
Apparently CSBR will not be using their platform to develop a drug portfolio of cancer drugs anymore. They are spinning off the division, putting Guy Malchi in charge, raising money, and will only end up with a minority position. The one drug they announced that we have and will pursue is being given over to this spinoff.
To everyone, please confirm anything and everything I've written here and previously about CSBR with CSBR before making any investment decisions.